Literature DB >> 25064383

Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder.

Soon-Beom Hong1, Jae-Won Kim1, Bum-Sung Choi1, Yun-Chul Hong2, Eun-Jin Park3, Min-Sup Shin1, Boong-Nyun Kim1, Hee-Jeong Yoo1, In-Hee Cho4, Soo-Young Bhang5, Soo-Churl Cho6.   

Abstract

Patients with attention-deficit/hyperactivity disorder (ADHD) appear to be more vulnerable to the development of other psychiatric disorders than the general population. The proposed neurotoxic mechanisms of manganese involve striatal dopamine neurotransmission, implicated in the pathophysiology of ADHD. We investigated whether the adverse impact of manganese is particularly pronounced in children with ADHD. Blood manganese concentration and diagnosis of ADHD were assessed in a general population of 890 children, aged 8-11 years. The main outcome measure was the Child Behavior Checklist (CBCL). A significant interaction was found between ADHD status and blood manganese level in predicting CBCL total problems score as well as anxiety/depression, social problems, delinquent behavior, aggressive behavior, internalizing problems, and externalizing problems. The directions of the interactions indicated that blood manganese level was more positively correlated with CBCL scores in ADHD children than in the healthy population. In ADHD children, only the fifth quintile of blood manganese concentration was significantly associated with the CBCL total problems score. ADHD children may be more vulnerable than the general school-age population to the neurotoxic effects of manganese exposure, which lead to an elevated risk of developing comorbid mental conditions.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  ADHD; CBCL; Dopamine; Manganese

Mesh:

Substances:

Year:  2014        PMID: 25064383     DOI: 10.1016/j.psychres.2014.05.049

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Manganese transporter genetics and sex modify the association between environmental manganese exposure and neurobehavioral outcomes in children.

Authors:  Karin Broberg; Tahir Taj; Stefano Guazzetti; Marco Peli; Giuseppa Cagna; Daniela Pineda; Donatella Placidi; Robert O Wright; Donald R Smith; Roberto G Lucchini; Karin Wahlberg
Journal:  Environ Int       Date:  2019-06-22       Impact factor: 9.621

2.  Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment.

Authors:  Pan Chen; Melissa Totten; Ziyan Zhang; Hana Bucinca; Keith Erikson; Abel Santamaría; Aaron B Bowman; Michael Aschner
Journal:  Expert Rev Neurother       Date:  2019-02-21       Impact factor: 4.618

Review 3.  Manganese and Developmental Neurotoxicity.

Authors:  Roberto Lucchini; Donatella Placidi; Giuseppa Cagna; Chiara Fedrighi; Manuela Oppini; Marco Peli; Silvia Zoni
Journal:  Adv Neurobiol       Date:  2017

Review 4.  Mechanisms of divalent metal toxicity in affective disorders.

Authors:  Archita Venugopal Menon; JuOae Chang; Jonghan Kim
Journal:  Toxicology       Date:  2015-11-10       Impact factor: 4.221

Review 5.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

Review 6.  Association between peripheral manganese levels and attention-deficit/hyperactivity disorder: a preliminary meta-analysis.

Authors:  Jun-Hao Shih; Bing-Yan Zeng; Pao-Yen Lin; Tien-Yu Chen; Yen-Wen Chen; Ching-Kuan Wu; Ping-Tao Tseng; Ming-Kung Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-07-18       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.